0000899243-16-028314.txt : 20160831
0000899243-16-028314.hdr.sgml : 20160831
20160831182517
ACCESSION NUMBER: 0000899243-16-028314
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160829
FILED AS OF DATE: 20160831
DATE AS OF CHANGE: 20160831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagent Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001369786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
BUSINESS PHONE: 847-908-1604
MAIL ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
FORMER COMPANY:
FORMER CONFORMED NAME: Sagent Holding Co.
DATE OF NAME CHANGE: 20090529
FORMER COMPANY:
FORMER CONFORMED NAME: NHS PHARMACEUTICALS
DATE OF NAME CHANGE: 20060720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OBERMAN ALLAN
CENTRAL INDEX KEY: 0001656585
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35144
FILM NUMBER: 161864194
MAIL ADDRESS:
STREET 1: C/O SAGENT PHARMACEUTICALS, INC.
STREET 2: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-29
1
0001369786
Sagent Pharmaceuticals, Inc.
SGNT
0001656585
OBERMAN ALLAN
C/O SAGENT PHARMACEUTICALS, INC.
1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG
IL
60195
1
1
0
0
Chief Executive Officer
Common Stock
2016-08-29
4
D
0
9459
21.75
D
92527
D
Common Stock
2016-08-29
4
D
0
92527
21.75
D
0
D
Stock Option to Buy
14.61
2016-08-29
4
D
0
108696
7.14
D
2026-02-22
Common Stock
108696
0
D
Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").
Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Merger Consideration.
Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
/s/ Allan Oberman
2016-08-31